Philipp Lurz
Latest contributions
The continuum of valvular heart disease: a lifetime management approach
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive perspective on valvular heart disease through the lens of lifetime management, highlighting the need for strategic planning across aortic, mitral, and tricuspid interventions, illustrating how treating one valve can influence the progression and management of others. Gain insights into optimal timing...
Transcatheter mitral valve replacement: LIVE Educational Case from University Medical Centre - Mainz, Germany
20 May 2026 – From EuroPCR 2026
This live educational case from University Medical Centre Mainz presents a stepwise transcatheter mitral valve replacement procedure. The session includes patient presentation, imaging analysis, detailed operator strategy, live procedural segments with audience interaction, and concludes with final results and key clinical learnings.
TAVI aortic regurgitation: LIVE Educational Case from University Medical Centre - Mainz, Germany
20 May 2026 – From EuroPCR 2026
This educational session reviews the management of pure native aortic regurgitation via TAVI, including indications and selection criteria for dedicated transcatheter heart valve devices. It details procedural planning steps such as anatomical assessment, imaging strategies, and device positioning, supplemented by a live case demonstration highlighting key...
Atrial mitral and tricuspid regurgitation
09 Apr 2026
M. Sitges, M. Adamo, P. Lurz, D. Muraru and T. De Potter guide you through understanding combined mitral regurgitation and tricuspid regurgitation in patients with atrial fibrillation.
From Guidelines to patients’ lives: how to apply and connect the community
17 Mar 2026
Watch this replay with M. Swaans, P. Lurz, M. Cikes and F. Praz to learn how to differentiate ventricular versus atrial secondary mitral regurgitation phenotypes and much more!
All about PCR’s Teaching Assessment Board (TAB)
03 Dec 2025
Learn how session feedback is compiled to create a virtuous cycle of continuous refinement for education in #interventionalcardiology
Transcatheter mitral valve replacement in practice
18 Nov 2025 – From PCR London Valves 2025
This session provides an in-depth overview of transcatheter mitral valve replacement (TMVR) in clinical practice, focusing on patient and anatomical suitability assessments including imaging parameters and risk factors for left ventricular outflow tract obstruction. It covers anatomical preparation techniques such as leaflet modification, prior clip removal,...
Iatrogenic atrial septum defect closure: a necessary procedure?
18 Nov 2025 – From PCR London Valves 2025
This session addresses the clinical considerations surrounding iatrogenic atrial septal defects (ASDs) resulting from transseptal procedures. It covers prevention of residual defects, diagnostic evaluation, criteria for closure, procedural timing, and management strategies for related complications, supported by illustrative clinical cases demonstrating decision-making nuances.
Tricuspid repair or replacement - Matching the patient to the procedural strategy
17 Nov 2025 – From PCR London Valves 2025
This session addresses the nuanced decision-making process in selecting appropriate transcatheter tricuspid repair or replacement strategies. It covers the current device landscape, patient selection criteria based on anatomical and clinical factors, and discusses emerging challenges such as pacing lead management, anticoagulation, and outcome definitions.
Early Career Research Award Final
17 Nov 2025 – From PCR London Valves 2025
Highlighting pioneering research in structural heart interventions, this session presents studies on the impact of transcatheter tricuspid valve replacement (TTVR) on left ventricular geometry and function, myocardial remodeling in aortic stenosis, physiological responses after mitral and tricuspid edge-to-edge repairs, advancing the understanding of device effects on...
Is iatrogenic atrial septum defect closure a necessary procedure?
17 Nov 2025 – From PCR London Valves 2025
Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure...
Mitral regurgitation: from guidelines to clinical practice
16 Nov 2025 – From PCR London Valves 2025
This LIVE case symposium brings mitral regurgitation guidelines into real clinical practice. Through step-by-step patient demonstrations and insightful discussion, the session explores how recommendations guide decision-making in ventricular and atrial secondary MR, how the heart team tailors therapy to individual anatomy and comorbidities, and how device iterations...
Late-Breaking Trials in transcatheter mitral, tricuspid and aortic interventions - Part 1
16 Nov 2025 – From PCR London Valves 2025
This session presents pivotal late-breaking trials in transcatheter mitral and aortic valve interventions. Explore one-year outcomes from the AltaValve early feasibility study featuring atrial fixation TMVR, interim results from the TARGET study assessing Cardiovalve for tricuspid regurgitation, five-year data on transapical TMVR, and outcomes of TAVI...
From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients
16 Nov 2025 – From PCR London Valves 2025
This session explores a full spectrum of therapeutic options for mitral and tricuspid regurgitation, focusing on the PASCAL Precision system for targeted repair and the SAPIEN M3 transcatheter mitral valve replacement. Through beating heart simulators, case discussions, and clinical evidence, participants will understand the versatility and...
Transcatheter tricuspid valve replacement: who to treat and how to implement into my practice
12 Nov 2025
In this on-demand webinar, F. Praz, P. Lurz, M. Adam, and T. Patterson explore TTVR, sharing key insights and the latest clinical evidence supporting TTVR.
Introducing the team behind PCR Mitral Focus Group
19 Aug 2025
Together with the Mitral Focus Group members, Co-Directors Philipp Lurz and Thomas Modine will work to align knowledge and collaborate globally to improve care for patients with mitral valve disease.
Repair and replace: latest insights in transcatheter treatment of mitral and tricuspid regurgitation
20 May 2025 – From EuroPCR 2025
Join Michael Mullen, Federico De Marco, and Philipp Lurz as they discuss the latest breakthroughs in the treatment of mitral and tricuspid regurgitation at EuroPCR 2025. In this roundtable session, they delve into both repair and replacement techniques, offering insights into new systems and their impact...
Tricuspid regurgitation and heart failure with preserved ejection fraction
11 Jun 2025
Watch the replay of this webinar with M. Adamo, M. Metra, K-P. Kresoja, P. Lurz, P. Ponikowski and M. Sitges and learn about mechanisms and risk factors for HFpEF and TR, and so much more!
Innovative approaches to refractory heart failure: devices and therapies to the rescue
23 May 2025 – From EuroPCR 2025
This session highlights innovative device-based therapies for refractory heart failure, emphasizing the integration of neuromodulation, decongestive strategies, and the synergy with pharmacological treatments. Case presentations illustrate the evolving landscape of advanced heart failure management.
Combined LAA closure and transcatheter mitral valve repair - LIVE Case
22 May 2025 – From EuroPCR 2025
An 82-year-old male patient with a history of PM (pacemaker) implantation in 2024, and ischaemic cardiomyopathy presented with symptomatic heart failure due to severe secondary mitral regurgitation and impaired LV function (EF 40 %). He also presented with recurrent gastro-intestinal bleeding while on DOAC for atrial...
The impact of paravalvular leak, permanent pacemaker implantation and the planning for reinterventions on lifetime management in TAVI patients
22 May 2025 – From EuroPCR 2025
How do paravalvular leak, pacemaker implantation and reintervention planning shape lifetime outcomes in TAVI patients?
This session examines these crucial aspects through the case of a 77-year-old male with bicuspid aortic valve stenosis, HFpEF and multiple comorbidities, including diabetes, obesity and sleep apnoea.
Follow the discussion to understand...
Pioneering innovation in the treatment of mitral and tricuspid regurgitation
20 May 2025 – From EuroPCR 2025
This interventional session explores therapeutic strategies for mitral and tricuspid regurgitation, focusing on the clinical decision-making process between repair and replacement. Through two clinical cases, a 78-year-old male patient with severe degenerative mitral regurgitation and an 88-year-old female patient with atrial functional mitral regurgitation, experts review available...
Tailoring transcatheter mitral therapies: a new era
20 May 2025 – From EuroPCR 2025
This session focuses on the evolving landscape of transcatheter mitral valve therapies. Learn about strategic programme development, patient phenotyping to guide device selection and repair versus replacement decisions, and the latest innovations and approvals in transcatheter mitral valve replacement.
How to tailor transcatheter mitral therapies in 2025? A new era
20 May 2025 – From EuroPCR 2025
In this discussion from EuroPCR 2025, Mayra Guerrero, Thomas Modine, and Philipp Lurz explore the evolving landscape of mitral valve treatment.
While transcatheter edge-to-edge repair (TEER) remains a safe and effective approach, it doesn't suit every patient. Alternatives like transcatheter mitral valve replacement (TMVR), annuloplasty, and NeoChord implantation...
Updates in tricuspid interventions: from the procedure to follow-up
15 Apr 2025
Watch the replay of this webinar with G. Nickenig, J. Dreyfus, S. Kar and P. Lurz and learn about the follow-up results of the TRILUMINATE trial, and so much more!
Primary tricuspid regurgitation: how can we avoid high-risk surgery?
08 Apr 2025
A 70-year-old male patient presents with severe dyspnea (NYHA III) and marked leg edema, alongside a complex medical history including hypertrophic cardiomyopathy, pulmonary hypertension, and liver fibrosis.
With invasive hemodynamic measurements indicating elevated pressures and reduced cardiac output, how would you approach the treatment of this patient,...
Author
Author
Multivalve disease: defining pathways for optimal assessment and treatment in the absence of good clinical evidence
26 Nov 2024 – From PCR London Valves 2024
Curious about managing multivalve disease in the absence of robust clinical evidence? This video is a must-watch!
You'll explore the latest strategies for assessing and treating this condition (including advanced multimodality investigations like echocardiography, magnetic resonance and cardiac catheterisation), and learn how to evaluate cardiopulmonary interactions and...
Recurrent and residual tricuspid regurgitation after transcatheter repair - Assessment and management
26 Nov 2024 – From PCR London Valves 2024
Join us as we delve into the critical topic of recurrent and residual tricuspid regurgitation after transcatheter repair. Gain valuable insights on how to avoid these complications, learn to assess the underlying mechanisms and severity, and explore the latest options for interventional treatment. This session, developed...
Transforming interventional care for patients with mitral regurgitation: simulation and case-based learning
26 Nov 2024 – From PCR London Valves 2024
Explore the differentiating features of the PASCAL Precision system for the treatment of patients with mitral regurgitation through simulation and case-based learning.
Advanced imaging in tricuspid TEER - LIVE case
26 Nov 2024 – From PCR London Valves 2024
Watch a LIVE case followed by a recorded case on how to use imaging in tricuspid TEER:
- A 64-year-old male with a history of CABG and COPD, ICD implantation (2013) mitraclip (2018) and poor LV function (25%), presented a torrential functional tricuspid regurgitation. The operators implanted 2...
